Navigation Links
COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
Date:12/16/2010

MURRIETA, Calif., Dec. 16, 2010 /PRNewswire/ -- COPAN has enjoyed widespread use of its flocked swabs line, branded as FLOQSwabs, in microbiology for the collection and transportation of bacterial and viral samples.

FLOQSwabs by COPAN have been shown through numerous independent studies to collect more sample and elute the entire sample thus improving the detection and diagnosis of infectious disease agents. In spite of this success, the company has remained committed to continual innovation to optimize the sample collection, preservation and maximize the release of the target analyte into numerous assay platforms. New research at COPAN has led to an important technological breakthrough in the yield of target nucleic acid from its FLOQSwabs.  In the case of Low Copy Numbers (LCN) when minute quantities of nucleic acid might be present in a sample, maximum yield of nucleic acid can make the difference between a positive or negative result.

Even though FLOQSwabs release almost the entire sample, nucleic acid has a tendency to be sticky and some residue can still attach to swab fibers. This risk is eliminated with COPAN's latest discovery in fiber treatment for flocked swabs. COPAN's high nucleic acid yield FLOQSwabs now deliver as much as 1 log more nucleic acid, equivalent to 3 PCR cycles less for detection. This demonstrable improvement is another milestone in the evolution of flocked swab technology and ensures the maximum sensitivity of assay. The recent discoveries are now the subject of a series of new patent applications by COPAN in the USA and in other countries around the world.

Worldwide, COPAN holds numerous patents for its original line of flocked swabs, FLOQSwabs.

About Copan Group

With a reputation for innovation in preanalytics, Copan is the leading manufacturer of collection and transport systems in the world. COPAN offers a complete range of microbial sampling products used for traditional culture analysis and molecular diagnostic assays. For more information, visit www.copanusa.com


'/>"/>
SOURCE Copan Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. COPAN Secures Japanese Patent for its Flocked Swab Innovation
2. Copan Redefines Automated Specimen Processing with Groundbreaking New Features
3. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
4. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. ERT Files Shelf Registration Statement
6. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
7. Chesley Files Class Action Against DePuy Orthopaedics
8. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
9. Peptimmune Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone
10. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
11. China-Biotics Files New Patent Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
Breaking Medicine Technology:
(Date:4/22/2017)... New Freedom, PA (PRWEB) , ... April 22, ... ... of healthcare experience to his role as Vice President of Sales and Business ... direction of key GPO/IDN business partner engagements, business development, and strategic planning for ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to ... youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and ... involved in violence in the United States. The study, Trends in Fighting ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Dudnyk has announced ... emphasizes the agency’s conviction that the full potential of specialty and orphan brands can ... appreciated and aligned. , “The Unifying Effect is at the heart of a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):